Lantheus Holdings, Inc.
$83.97
▲
0.53%
2026-04-21 07:56:00
www.lantheus.com
NGM: LNTH
Explore Lantheus Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.47 B
Current Price
$83.97
52W High / Low
$108.91 / $47.25
Stock P/E
23.41
Book Value
$16.87
Dividend Yield
—
ROCE
16.66%
ROE
21.45%
Face Value
—
EPS
$3.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,193
Beta
-0.12
Debt / Equity
57.19
Current Ratio
2.7
Quick Ratio
2.51
Forward P/E
12.81
Price / Sales
3.4
Enterprise Value
$5.47 B
EV / EBITDA
14.31
EV / Revenue
3.55
Rating
None
Target Price
$91.38
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | China SXT Pharmaceuticals, Inc. | $2.06 | — | $1.97 M | — | -17.13% | -50.3% | $1,046.98 / $1.25 | $26.16 |
| 2. | InMed Pharmaceuticals Inc. | $0.72 | — | $2.4 M | — | -57.63% | -97.2% | $7.98 / $0.57 | $3.42 |
| 3. | Neurocrine Biosciences, Inc. | $130.77 | 28.05 | $13.18 B | — | 16.37% | 16.38% | $160.18 / $98.95 | $32.5 |
| 4. | Elanco Animal Health Incorporated | $22.34 | — | $11.2 B | — | 2.14% | -3.67% | $27.72 / $8.02 | $13.17 |
| 5. | SIGA Technologies, Inc. | $4.57 | 14.06 | $327.41 M | 0% | 11.76% | 11.23% | $9.62 / $4.29 | $2.78 |
| 6. | BGM Group Ltd. | $0.36 | — | $59.42 M | — | -0.81% | -3.37% | $17.17 / $0.27 | $1.85 |
| 7. | Cumberland Pharmaceuticals Inc. | $3.15 | — | $47.57 M | — | -6.97% | -12.17% | $6.27 / $1.85 | $1.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 406.79 M | 384.01 M | 378.05 M | 372.76 M | 391.11 M |
| Operating Profit | 77.18 M | 43.62 M | 87.97 M | 106.79 M | 111.71 M |
| Net Profit | 54.09 M | 27.77 M | 78.75 M | 72.94 M | -11.79 M |
| EPS in Rs | 0.83 | 0.43 | 1.21 | 1.12 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.54 B | 1.53 B | 1.3 B | 935.06 M |
| Operating Profit | 315.56 M | 448.56 M | 364.64 M | 36.2 M |
| Net Profit | 233.56 M | 312.44 M | 326.66 M | 28.07 M |
| EPS in Rs | 3.59 | 4.8 | 5.02 | 0.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.23 B | 1.98 B | 1.65 B | 1.32 B |
| Total Liabilities | 1.14 B | 892.33 M | 835.26 M | 874.11 M |
| Equity | 1.09 B | 1.09 B | 815.89 M | 447.15 M |
| Current Assets | 899.96 M | 1.33 B | 1.09 B | 677.62 M |
| Current Liabilities | 333.42 M | 240.53 M | 187.35 M | 247.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 390.14 M | 544.75 M | 305.26 M | 281.78 M |
| Investing CF | -627.17 M | -226.01 M | 5.94 M | -276.55 M |
| Financing CF | -316.58 M | -118.54 M | -13.06 M | 311.69 M |
| Free CF | 348.64 M | 465.12 M | 258.7 M | 263.43 M |
| Capex | -41.5 M | -79.62 M | -46.55 M | -18.35 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 0.5% | 18.32% | 38.65% | — |
| Earnings Growth % | -25.25% | -4.35% | 1063.86% | — |
| Profit Margin % | 15.15% | 20.37% | 25.2% | 3% |
| Operating Margin % | 20.47% | 29.24% | 28.13% | 3.87% |
| Gross Margin % | 61.1% | 64.43% | 54.73% | 62.21% |
| EBITDA Margin % | 26.18% | 33.59% | 37.87% | 8.75% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.